The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia

Leukemia

Volumn 28, Issue 6, 2014, Pages 1360-1363

  Giannoudis, A ^a   Davies, A ^a   Harris, R J ^a   Lucas, C M ^a   Pirmohamed, M ^b   Clark, R E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; IMATINIB; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; PROBENECID; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; CD34 ANTIGEN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG TREATMENT FAILURE; DRUG UPTAKE; HUMAN; LETTER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; CONTROLLED STUDY; CYTOGENETICS; DRUG TRANSPORT; HUMAN CELL; MAJOR CLINICAL STUDY;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PIPERAZINES; PROGNOSIS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84902084338     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.38     Document Type: Letter

References (15)

1. Francis S, Lucas C, Lane S, Wang L, Watmough S, Knight K et al. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. Leuk Res 2013; 37: 752-758.
2. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-1029. (Pubitemid 47629897)
3. Steinbach D, Legrand O. ABC transporters and drug resistance in leukaemia: Was P-gp nothing but the first head of the Hydra? Leukaemia 2007; 21: 1172-1176.
4. Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ ABCG2 drug pump. Blood 2004; 104: 2940-2942. (Pubitemid 39434984)
5. Thomas J, Wang L, Clark RE, Pirmohammed M. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 2004; 104: 3739-3745. (Pubitemid 39564452)
6. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important determinant of the response to imatinib in chronic myeloid leukaemia. Clin Pharm Therapeut 2008; 83: 258-264.
7. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008; 14: 3141-3148.
8. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794-2799.
9. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27: 6041-6051.
10. Schmittgen TD, Livak KJ. Analyzing real-Time PCR data by the comparative CT method. Nat Protoc 2008; 3: 1101-1108. (Pubitemid 351818697)
11. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CD34+ cells and is inhibiteb by imatinib mesylate. Blood 2006; 108: 1370-1373. (Pubitemid 44232038)
12. Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C et al. c-Myc oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myeloid leukemia. Mol Cancer Res 2011; 8: 1054-1066.
13. Tang L, Bergevoet SM, Gilissen C, de Witte T, Jansen JH, Van Der Reijden BA et al. Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol 2010; 10: 1-9.
14. Giannoudis A, Davies A, Lucas C, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): Implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008; 112: 3348-3354.
15. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterisation of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001; 276: 46400-46407.